|
Apr 30
|
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
|
|
Apr 25
|
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 24
|
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Apr 24
|
3 Biotech Stocks With Skyrocketing Potential: April 2024
|
|
Apr 22
|
10 Best Performing Biotech ETFs in 2024
|
|
Apr 18
|
Intra-Cellular Therapies Prices Public Offering of Common Stock
|
|
Apr 17
|
Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point
|
|
Apr 17
|
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
|
|
Apr 17
|
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
|
|
Apr 16
|
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
|
|
Apr 16
|
Intra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores Big
|
|
Apr 16
|
Intra-Cellular builds case for depression drug with late-stage trial win
|
|
Apr 16
|
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
|
|
Mar 24
|
Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467%
|
|
Mar 19
|
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
|
|
Mar 12
|
Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares
|
|
Mar 6
|
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
|
|
Feb 15
|
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 15
|
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 13
|
Biotech Leader Intra-Cellular Therapies Nears Buy Point Ahead Of Earnings Report
|